Article: Otsuka Pharmaceutical and Bristol-Myers Squibb announced that the FDA approved the supplemental NDA for the atypical antipsychotic Abilify (aripiprazole) for the treatment of schizophrenia in adolescents aged 13-17 years.(Pipeline)

Article: Antipsychotic Abilify (aripiprazole) approved for ...
Drug Week;  July 9, 2004 ;     700+ words ... ... amp; NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical ... chief executive officer, Bristol-Myers Squibb. "For patients with schizophrenia ... authorization for Abilify in Europe. Bristol-Myers Squibb and Otsuka will co-promote Abilify ...

Article: Positive maintenance data for B-MS/Otsuka's ...
Pharma Marketletter;  May 22, 2006 ;     700+ words ...Maintenance therapy with the US drug major Bristol-Myers Squibb and Otsuka Pharmaceutical's co-developed atypical antipsychotic Abilify (aripiprazole) significantly delayed the time to relapse in adults with bipolar I disorder who had been ...

Article: Strong results for B-MS/Otsuka's Abilify.(Bristol-Myers ...
Pharma Marketletter;  March 20, 2006 ;     700+ words ...US drug major Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical says that their co-devloped antipsychotic, Abilify (aripiprazole) demonstrated statistically-superior effectiveness to the standard of care in schizophrenia. Data presented ...

Article: B-MS/Otsuka launch 2 new forms of Abilify.(Bristol-Myers ...
Pharma Marketletter;  February 13, 2006 ;     661 words ...US drug major Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have launched two new formulations of their antipsychotic Abilify (aripiprazole): a 2mg strength tablet, to help physicians titrate patients to an effective dose, and ...

Article: Bristol-Myers Squibb Co.(CORPORATE)(Otsuka ...
MondayMorning;  October 19, 2009 ;     700+ words ...Bristol-Myers Squibb Co. (New York) cut the sales force for its second best-selling drug, the antipsychotic Abilify, six months after extending its contract to market the product with Tokyo-based Otsuka Pharmaceutical Co. About 25 ...

Article: FDA clears new indication for Abilify.(Otsuka Pharmaceutical ...
Pharma Marketletter;  March 21, 2005 ;     663 words ... ... Japan-based Otsuka Pharmaceutical and the USA's Bristol-Myers Squibb say that the US Food and Drug Administration has approved a new use for their antipsychotic Abilify (ariprazole). The agent is now available for the maintenance ...

Article: B-MS and Otsuka introduce Abilify 5mg.(Bristol-Myers ...
Pharma Marketletter;  January 17, 2005 ;     658 words ...US health care giant Bristol-Myers Squibb and Japan's Otsuka Pharmaceuticals (UK) have launched a new 5mg version of their next-generation antipsychotic Abilify (aripiprazole) for the treatment of schizophrenia. The drug is already available ...